|
2021
|
Invention
|
Triple combination to treat b-cell malignancies. A triple combination of agents comprising: (i) a... |
|
|
Invention
|
Triple combination to treat b-cell malignancies.
Methods for treating B-cell malignancies are pr... |
|
|
Invention
|
Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-... |
|
|
Invention
|
Novel compounds as modulators of protein kinases.
The present invention provides PI3K protein ki... |
|
|
Invention
|
Novel selective pi3k delta inhibitors.
The present invention relates to selective inhibitors of ... |
|
|
Invention
|
Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to tre... |
|
2020
|
Invention
|
Combination of anti-cd20 antibody and pi3 kinase selective inhibitor.
Highly effective combinati... |
|
2019
|
Invention
|
Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof. The pre... |
|
2018
|
Invention
|
Selective dual inhibitors of pi3 delta and gamma protein kinases.
The present invention relates ... |
|
|
Invention
|
Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma. The... |
|
|
Invention
|
Calcium release-activated calcium channel modulators for treating hematological and solid cancers... |
|
|
Invention
|
Composition and method for treating diffuse large b-cell lymphoma. The present invention relates ... |
|
|
Invention
|
Novel modulators of calcium release-activated calcium channel and methods for treatment of non-sm... |
|
|
Invention
|
Crac channel modulators for treating esophageal cancer.
The present invention relates to the use... |
|
|
Invention
|
Crac channel modulators for treating esophageal cancer. The present invention relates to the use ... |
|
2017
|
Invention
|
Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 ant... |
|
|
Invention
|
Novel compounds as modulators of gpr-119.
The present invention relates to novel compounds of fo... |
|
|
Invention
|
Combination of anti-cd20 antibody and pi3 kinase selective inhibitor. Highly effective combinatio... |
|
2015
|
Invention
|
Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a co... |
|
|
Invention
|
Compounds as modulators of gpr-119. The present invention relates to novel compounds of formula (... |
|
|
Invention
|
Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kina... |
|
|
Invention
|
Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations. The pr... |
|
|
Invention
|
Inhibitors of glutaminase. The present disclosure provides compounds of formula (I) to (III) as g... |
|
|
Invention
|
Glutaminase inhibitors. The present disclosure provides compounds of formula (I) to (III) as glut... |
|
2014
|
Invention
|
Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstituted -3h-[1,2,3]triazolo[4,5-b... |
|
|
Invention
|
Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors. The present disclosur... |
|
|
Invention
|
Novel selective pi3k delta and/or gamma protein kinase inhibitors. The present disclosure provide... |
|
|
Invention
|
Dual selective pi3 delta and gamma kinase inhibitors. The present invention relates to dual delta... |
|
2013
|
Invention
|
Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma k... |
|
|
Invention
|
Selective pi3k delta inhibitors. The present invention relates to selective inhibitors of PI3K de... |
|
|
Invention
|
Novel selective pi3k delta inhibitors. The present invention relates to selective inhibitors of P... |
|
|
Invention
|
Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chr... |
|
|
Invention
|
Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-... |
|
|
Invention
|
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]... |
